Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:35:19 2026-02-12 am EST			5-day change	1st Jan Change
23.60 ^EUR	-1.46%		+2.39%	-7.81%

Feb. 11	Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region	MT
Feb. 11	Swiss stocks - Factors to watch on February 11	RE

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206

Published on 12/09/2025 at 07:25 am EST - Modified on 12/09/2025 at 07:41 am EST

Reuters

Latest news about Formycon AG

Feb. 11	Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region	MT
Feb. 11	Swiss stocks - Factors to watch on February 11	RE
Feb. 11	Formycon says Lotus Pharmaceutical to commercialize its Keytruda biosimilar in Asia-Pacific	RE
Dec. 23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
Dec. 23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE
Dec. 23	Formycon AG and Bioeq AG Announce the U.S. Food and Drug Administration Approves Nufymco®?	CI
Dec. 21	INDEX MONITOR: Numerous Changes in MDax and SDax - Dax Remains Unchanged	DP
Dec. 18	Formycon AG(XTRA:FYB) dropped from Germany SDAX (Total Return) Index	CI
Dec. 09	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada	MT
Dec. 09	Formycon AG and Zydus Lifesciences Limited Partner for Exclusive Licensing and Supply Agreement of FYB206, a Biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	CI
Dec. 09	Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar	DP
Dec. 09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206	RE
Dec. 09	Formycon Ag and Zydus Lifesciences Limited Enter into Strategic Partnership for the Exclusive Licensing and Supply of Checkpoint Inhibitor Fyb206	CI
Dec. 04	Formycon AG and MS Pharma Sign Exclusive Commercialization Partnership for Keytruda®? Biosimilar Candidate FYB206 for the MENA Region	CI
Dec. 04	Formycon Secures First Marketing Partnership for Keytruda Biosimilar	DP
Dec. 04	Formycon, MS Pharma Enter Licensing Deal for Keytruda Biosimilar in MENA	MT
Dec. 04	Stoxx Ltd. announces December 2025 review results of Dax indices	RE
Dec. 04	Newcomers TKMS and Aumovio Join MDax; Dax Remains Unchanged	RE
Dec. 04	Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for MENA region	RE
Nov. 24	FORMYCON : Berenberg remains its Buy rating	ZD
Nov. 24	Formycon Appoints NTC as Exclusive Commercial Partner for Eylea Biosimilar in Italy	MT
Nov. 24	Ntc becomes commercialization partner for Formycon's Eylea® biosimilar FYB203/Baiama® in Italy	RE
Nov. 24	Formycon AG and NTC S.r.l. Jointly Announce Eylea Biosimilar FYB203/Baiama®? in Italy	CI
Nov. 20	Formycon Ag and Bioeq Ag Jointly Announce an Agreement with Sandoz Ag for the Commercialization of Epruvy in Germany	CI
Nov. 17	FORMYCON : RBC reaffirms its Buy rating	ZD

Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.

Employees

250

Sector

Biotechnology & Medical Research

Calendar

Apr. 22 - Q4 2025 Earnings Release (Projected)

More about the company